Savara has mapped out a simple destiny in pursuit of approval for its lead therapy. Recent interest in and support of Savara is overblown. Single minded focus on its lead therapy allows Savara to ...
Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company with a market capitalization of $691 million focused on developing novel therapies for rare respiratory diseases, stands at a pivotal juncture as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results